Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Impax Laboratories
Impax Laboratories
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
US court lifts modified consent decree on Xellia’s Cleveland facility
The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Lonza's AI-enabled small molecule development tool launches
The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Autoscribe Informatics’ new Australia office supports business growth
The company's move to West Lakes Adelaide expands its ability to service the Asia Pacific region in digitalising laboratory information
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Manufacturing
Federal Equipment online auction of Impax packaging, processing and pharma assets
Do not miss Impax Laboratories’ pharmaceutical equipment auction 27–28 July
Manufacturing
Global online auction
Global Online Auction of quality surplus packaging, processing and pharmaceutical assets formerly of Impax Laboratories
Manufacturing
Impax Laboratories in capsule deal with Banner Pharmacaps
The two companies will collaborate on the supply of two softgel capsule products
Research & Development
GSK to sell Impax treatment for Parkinson’s Disease
Pays Impax US$11.5m upfront for exclusive licence
Subscribe now